World Health Organization Sounds Concern Over Acute Scarcity of Obesity Injections

Under a tenth of people eligible to benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it releases its initial advice on the drugs.

Considering over a billion individuals worldwide currently obese, it is urging more widespread and fairer access to GLP-1 medication.

According to projections, over two billion could be obese by 2030 unless action is taken.

"The latest guidance affirms that obesity is a chronic disease that can be treated with thorough and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are key hurdles to broad availability to the jabs that can assist patients in reducing substantial body mass, notes the organization.

Skinny Jab Supply Crisis

Even in the present best projected scenario, the supply of these medications could only cover about 100 million people – fewer than 10% of the global need, as stated by the health organization.

The recommendation encourages governments and firms to expand access, via measures including patent sharing.

A patent on the active ingredient – the main component of the drug Wegovy – is due to expire in a number of countries in 2026.

How Weight-Loss Injections Operate

These medications mimick a body's own hormone to slow digestion, curb appetite and boost satiety so individuals eat less.

People typically see weight reduction within a few weeks of commencing the weekly injections.

Evidence points to people may regain a significant portion within a year of discontinuing the medication, as their normal hunger resume.

Being overweight or obese increases your chance for experiencing health problems, including type 2 diabetes, heart disease, stroke, and certain cancers.

Obesity concerns people in all nations and was responsible for millions of deaths worldwide in 2024, as per the health agency.